Leeward Financial Partners LLC Raises Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Leeward Financial Partners LLC boosted its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 184.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,477 shares of the biotechnology company’s stock after buying an additional 1,606 shares during the period. Leeward Financial Partners LLC’s holdings in Axon Enterprise were worth $775,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. ICA Group Wealth Management LLC purchased a new stake in Axon Enterprise in the 4th quarter worth $26,000. Trivant Custom Portfolio Group LLC purchased a new stake in Axon Enterprise in the 1st quarter worth $31,000. BKM Wealth Management LLC purchased a new stake in Axon Enterprise in the 4th quarter worth $32,000. First PREMIER Bank purchased a new position in shares of Axon Enterprise during the first quarter valued at about $33,000. Finally, Key Financial Inc grew its position in shares of Axon Enterprise by 367.6% during the fourth quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Transactions at Axon Enterprise

In other news, Director Julie A. Cullivan sold 993 shares of the stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the sale, the director now directly owns 4,553 shares of the company’s stock, valued at approximately $1,282,671.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Julie A. Cullivan sold 993 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the completion of the transaction, the director now owns 4,553 shares in the company, valued at approximately $1,282,671.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey C. Kunins sold 43,668 shares of the company’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $309.94, for a total transaction of $13,534,459.92. Following the transaction, the insider now owns 189,719 shares of the company’s stock, valued at approximately $58,801,506.86. The disclosure for this sale can be found here. Insiders have sold a total of 89,447 shares of company stock valued at $27,684,677 in the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Axon Enterprise Stock Up 1.2 %

Shares of AXON stock traded up $3.38 during trading hours on Wednesday, reaching $296.56. 175,280 shares of the company’s stock were exchanged, compared to its average volume of 492,004. The stock’s 50 day moving average is $294.99 and its 200-day moving average is $285.77. The company has a market cap of $22.38 billion, a price-to-earnings ratio of 85.73 and a beta of 0.95. The company has a current ratio of 2.91, a quick ratio of 2.55 and a debt-to-equity ratio of 0.37. Axon Enterprise, Inc. has a fifty-two week low of $175.37 and a fifty-two week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The company had revenue of $460.74 million for the quarter, compared to analyst estimates of $441.57 million. During the same period in the prior year, the company earned $0.51 earnings per share. The firm’s revenue was up 34.3% on a year-over-year basis. Analysts predict that Axon Enterprise, Inc. will post 2.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AXON has been the subject of a number of research analyst reports. Barclays raised their price objective on Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a research report on Wednesday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a research note on Tuesday, May 7th. Argus started coverage on shares of Axon Enterprise in a research note on Wednesday, March 13th. They set a “buy” rating and a $380.00 price target for the company. Craig Hallum lifted their price target on shares of Axon Enterprise from $325.00 to $370.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and an average price target of $335.27.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.